JP2024500354A - ヘテロ二量体化のための直交変異 - Google Patents

ヘテロ二量体化のための直交変異 Download PDF

Info

Publication number
JP2024500354A
JP2024500354A JP2023535392A JP2023535392A JP2024500354A JP 2024500354 A JP2024500354 A JP 2024500354A JP 2023535392 A JP2023535392 A JP 2023535392A JP 2023535392 A JP2023535392 A JP 2023535392A JP 2024500354 A JP2024500354 A JP 2024500354A
Authority
JP
Japan
Prior art keywords
domain
sequence
mutation
amino acid
terminus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535392A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500354A5 (https=
Inventor
ジョナサン ハリー デイビス，
ニコラス エム． マーシャル，
Original Assignee
インベンラ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インベンラ， インコーポレイテッド filed Critical インベンラ， インコーポレイテッド
Publication of JP2024500354A publication Critical patent/JP2024500354A/ja
Publication of JP2024500354A5 publication Critical patent/JP2024500354A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
JP2023535392A 2020-12-10 2021-12-10 ヘテロ二量体化のための直交変異 Pending JP2024500354A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063123915P 2020-12-10 2020-12-10
US63/123,915 2020-12-10
PCT/US2021/062951 WO2022125986A1 (en) 2020-12-10 2021-12-10 Orthogonal mutations for heterodimerization

Publications (2)

Publication Number Publication Date
JP2024500354A true JP2024500354A (ja) 2024-01-09
JP2024500354A5 JP2024500354A5 (https=) 2024-05-30

Family

ID=81974005

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535392A Pending JP2024500354A (ja) 2020-12-10 2021-12-10 ヘテロ二量体化のための直交変異

Country Status (10)

Country Link
US (2) US12312418B2 (https=)
EP (1) EP4259194A4 (https=)
JP (1) JP2024500354A (https=)
KR (1) KR20230118612A (https=)
CN (1) CN116867514A (https=)
AU (1) AU2021397322A1 (https=)
CA (1) CA3207821A1 (https=)
IL (1) IL303518A (https=)
MX (1) MX2023006899A (https=)
WO (1) WO2022125986A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023245021A2 (en) * 2022-06-14 2023-12-21 Invenra Inc. Multispecific binding agents that target cd25 and/or ctla4 and uses thereof
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
JP2016506377A (ja) * 2012-11-27 2016-03-03 アジュ ユニバーシティ インダストリー−アカデミック コーポレーション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
WO2019204522A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Binding molecules
JP2019534277A (ja) * 2016-10-19 2019-11-28 インベンラ， インコーポレイテッド 抗体構築物
US20190367628A1 (en) * 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
JP2019536734A (ja) * 2016-08-10 2019-12-19 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
US20200255522A1 (en) * 2017-10-30 2020-08-13 Hoffmann-La Roche Inc. Method for in vivo generation of multispecific antibodies from monospecific antibodies
WO2020216878A1 (en) * 2019-04-25 2020-10-29 F. Hoffmann-La Roche Ag Generation of antibody-derived polypeptides by polypeptide chain exchange
WO2021168379A1 (en) * 2020-02-20 2021-08-26 Win Therapeutics, Inc. Bispecific gd2 and b7h2 binding molecules and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
HK1220465A1 (zh) * 2013-03-06 2017-05-05 Merrimack Pharmaceuticals, Inc. 抗c-met串联fc双特异性抗体
WO2016130516A1 (en) * 2015-02-09 2016-08-18 Research Development Foundation Engineered immunoglobulin fc polypeptides displaying improved complement activation
WO2018148447A1 (en) * 2017-02-08 2018-08-16 Adimab, Llc Antibody heavy chain variable domains targeting the nkg2d receptor

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537416A (ja) * 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
JP2016506377A (ja) * 2012-11-27 2016-03-03 アジュ ユニバーシティ インダストリー−アカデミック コーポレーション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ 抗体重鎖不変部位の異種二量体、高効率の形成を誘導するｃｈ３ドメイン変異体対、その作製方法および用途
JP2019536734A (ja) * 2016-08-10 2019-12-19 アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションＡｊｏｕ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎｄｕｓｔｒｙ−Ａｃａｄｅｍｉｃ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ ヘテロダイマーＦｃ融合サイトカインおよびそれを含む医薬組成物
JP2019534277A (ja) * 2016-10-19 2019-11-28 インベンラ， インコーポレイテッド 抗体構築物
US20200255522A1 (en) * 2017-10-30 2020-08-13 Hoffmann-La Roche Inc. Method for in vivo generation of multispecific antibodies from monospecific antibodies
WO2019204522A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Binding molecules
US20190367628A1 (en) * 2018-06-01 2019-12-05 Novartis Ag Binding molecules against bcma and uses thereof
WO2020216878A1 (en) * 2019-04-25 2020-10-29 F. Hoffmann-La Roche Ag Generation of antibody-derived polypeptides by polypeptide chain exchange
WO2021168379A1 (en) * 2020-02-20 2021-08-26 Win Therapeutics, Inc. Bispecific gd2 and b7h2 binding molecules and methods of use

Also Published As

Publication number Publication date
AU2021397322A9 (en) 2024-06-20
WO2022125986A1 (en) 2022-06-16
AU2021397322A1 (en) 2023-07-06
KR20230118612A (ko) 2023-08-11
EP4259194A1 (en) 2023-10-18
US20260078202A1 (en) 2026-03-19
US20220363782A1 (en) 2022-11-17
CN116867514A (zh) 2023-10-10
IL303518A (en) 2023-08-01
EP4259194A4 (en) 2025-03-19
US12312418B2 (en) 2025-05-27
MX2023006899A (es) 2023-09-04
CA3207821A1 (en) 2022-06-16

Similar Documents

Publication Publication Date Title
CN107207592B (zh) 结构域交换的抗体
US10562982B2 (en) Methods for producing Fabs and bi-specific antibodies
JP7138046B2 (ja) 二特異性抗体基幹
JP7123063B2 (ja) 抗体ドメインの好ましい対形成
JP2018138035A (ja) 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃ ｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
US20260078202A1 (en) Orthogonal mutations for heterodimerization
EP3728328A1 (en) Bispecific antigen binding construct
CN118843796A (zh) 稳定的单一免疫球蛋白可变结构域

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260303